跳至主要内容
临床试验/ACTRN12610000188033
ACTRN12610000188033已完成2 期

TROG 99.02 A prospective single arm non randomised study of concurrent radiation and chemotherapy for the organ conserving treatment of early anal canal cancer assessed by colostomy free survival and late toxicity.

Trans-Tasman Radiation Oncology Group Inc (TROG)0 个研究点目标入组 58 人开始时间: 2010年3月2日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
58

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment

入排标准

年龄范围
o limit 至 o limit(—)
性别
All

入选标准

  • squamous cell cancer including basaloid variant
  • Stage T1 and T2 <4cm, N0 or N1, M0
  • Performance status WHO grade 0,1,2
  • adequate bone marrow, liver and renal function

排除标准

  • anal tumours of other histology eg adenocarcinoma
  • anal margin tumours
  • patients presenting with recurrent disease after prior excision
  • history of ischaemic heart disease where 5FU considered a cardiac hazard
  • impaired control of anal shpincter
  • known immunosuppression eg HIV +ve or AIDS
  • pregnant or lactating women

研究者

发起方
Trans-Tasman Radiation Oncology Group Inc (TROG)

相似试验